Introduction：Basic information about CAS 149979-74-8|Terbogrel, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Terbogrel |
|---|
| CAS Number | 149979-74-8 | Molecular Weight | 405.49300 |
|---|
| Density | 1.13g/cm3 | Boiling Point | 601.3ºC at 760mmHg |
|---|
| Molecular Formula | C23H27N5O2 | Melting Point | / |
|---|
| MSDS | / | Flash Point | 317.4ºC |
|---|
Names
| Name | (E)-6-[3-[(N'-tert-butyl-N-cyanocarbamimidoyl)amino]phenyl]-6-pyridin-3-ylhex-5-enoic acid |
|---|
| Synonym | More Synonyms |
|---|
Terbogrel BiologicalActivity
| Description | Terbogrel is an orally available thromboxane A2 receptor antagonist and a thromboxane A2 synthase inhibitor, with both IC50s of about 10 nM. |
|---|
| Related Catalog | Signaling Pathways >>GPCR/G Protein >>Prostaglandin ReceptorResearch Areas >>Cardiovascular Disease |
|---|
| Target | IC50: apr 10 nM (thromboxane A2 receptor), appr 10 nM (thromboxane A2 synthase)[1] |
|---|
| In Vitro | Pretreatment of platelets with terbogrel 1 μM completely inhibits thrombin-induced thromboxane A2 formation (2±1 ng/mL) but does not result in any inhibition of platelet aggregation. Terbogrel (1 μM) completely inhibits U46619-induced platelet aggregation, and the IC50 value is 10 nM. Terbogrel inhibits both platelet aggregation and thromboxane A2 formation with an IC50 of about 10 nM[1]. Terbogrel inhibits the thromboxane A2 synthase in human gel-filtered platelets with an IC50 value of 4.0 ± 0.5 nM. Terbogrel blocks the thromboxane A2/endoperoxide receptor on washed human platelets with an IC50 of 11 ± 6 nM (n = 2) and with an IC50 of 38 ± 1 nM (n = 15) in platelet-rich plasma. Terbogrel inhibits the collagen-induced platelet aggregation in human platelet-rich plasma and whole blood with an IC50 of 310 ± 18 nM (n = 8) and 52 ± 20 nM (n = 6), respectively[2]. |
|---|
| In Vivo | Terbogrel (0.1−3.0 mg/kg) demonstrates an impressive antithrombotic efficacy in rabbits. Terbogrel (10 mg/kg, po) is rapidly and well (90%) absorbed with a systemic availability of about 30% in rats[2]. |
|---|
| References | [1]. Muck S, et al. Effects of terbogrel on platelet function and prostaglandin endoperoxide transfer. Eur J Pharmacol. 1998 Feb 26;344(1):45-8. [2]. Soyka R, et al. Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors. J Med Chem. 1999 Apr 8;42(7):1235-49. |
|---|
Chemical & Physical Properties
| Density | 1.13g/cm3 |
|---|
| Boiling Point | 601.3ºC at 760mmHg |
|---|
| Molecular Formula | C23H27N5O2 |
|---|
| Molecular Weight | 405.49300 |
|---|
| Flash Point | 317.4ºC |
|---|
| Exact Mass | 405.21600 |
|---|
| PSA | 110.40000 |
|---|
| LogP | 4.86918 |
|---|
| Vapour Pressure | 2.63E-15mmHg at 25°C |
|---|
| Index of Refraction | 1.579 |
|---|
| InChIKey | XUTLOCQNGLJNSA-RGVLZGJSSA-N |
|---|
| SMILES | CC(C)(C)N=C(NC#N)Nc1cccc(C(=CCCCC(=O)O)c2cccnc2)c1 |
|---|
| Storage condition | 2-8℃ |
|---|
Synonyms
| Terbogrel |
| Terbogrel (USAN/INN) |
| BIBV 308 |
| BIBV-308-SE |
